Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Melanoma × Radionuclide Imaging × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Odontogenic Cysts 2 Lung Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Melanoma 1 Liver Neoplasms 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms 1 Anus Neoplasms 1

Interventions

pembrolizumab 50 Nivolumab 49 Ipilimumab 27 Cyclophosphamide 15 Specimen Handling 10 Radiosurgery 10 Magnetic Resonance Spectroscopy 10 fludarabine 9 Opdualag 9 Biopsy 8 relatlimab 7 binimetinib 7 aldesleukin 7 Interleukin-2 7 Blood Specimen Collection 7 encorafenib 5 cemiplimab 5 Paclitaxel 5 Immunotherapy 5 Bevacizumab 5 toripalimab 4 atezolizumab 4 Temozolomide 4 CTLA-4 Antigen 4 trametinib 3 spartalizumab 3 lifileucel 3 fludarabine phosphate 3 dabrafenib 3 Surgical Procedures, Operative 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06666790 2024-10-31

DermaSensor Postmarket Surveillance Study

DermaSensor, Inc.

Phase NA Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡